| 0 |
HEART ALTERNATION |
1 |
0.0125 |
| 1 |
HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION |
3 |
0.0108 |
| 2 |
CD4 LYMPHOCYTES INCREASED |
2 |
0.0086 |
| 3 |
MESENTERIC NEOPLASM |
1 |
0.0078 |
| 4 |
VIRAL LOAD ABNORMAL |
1 |
0.0057 |
| 5 |
DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION |
1 |
0.0045 |
| 6 |
T-LYMPHOCYTE COUNT DECREASED |
3 |
0.0044 |
| 7 |
MUSCULOSKELETAL DEFORMITY |
1 |
0.0043 |
| 8 |
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS |
1 |
0.0039 |
| 9 |
ABDOMINAL WALL HAEMORRHAGE |
1 |
0.0038 |
| 10 |
PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT |
3 |
0.0034 |
| 11 |
GASTROENTERITIS ROTAVIRUS |
1 |
0.0032 |
| 12 |
ALLERGY TO ARTHROPOD BITE |
1 |
0.0031 |
| 13 |
VIRAL LOAD INCREASED |
12 |
0.0031 |
| 14 |
BLOOD HIV RNA INCREASED |
5 |
0.0028 |
| 15 |
UTERINE MASS |
1 |
0.0024 |
| 16 |
VIROLOGIC FAILURE |
9 |
0.0017 |
| 17 |
DIAPHRAGMATIC PARALYSIS |
1 |
0.0017 |
| 18 |
PRODUCT RESIDUE PRESENT |
9 |
0.0017 |
| 19 |
ACTIVITIES OF DAILY LIVING DECREASED |
1 |
0.0016 |
| 20 |
VIRAEMIA |
2 |
0.0014 |
| 21 |
LABELLED DRUG-DRUG INTERACTION ISSUE |
2 |
0.0014 |
| 22 |
SYPHILIS |
1 |
0.0014 |
| 23 |
VIRAL MUTATION IDENTIFIED |
5 |
0.0014 |
| 24 |
METAPNEUMOVIRUS INFECTION |
1 |
0.0013 |
| 25 |
MUSCLE DISCOMFORT |
1 |
0.0013 |
| 26 |
PATHOGEN RESISTANCE |
10 |
0.0011 |
| 27 |
IDIOSYNCRATIC DRUG REACTION |
1 |
0.0010 |
| 28 |
GENOTYPE DRUG RESISTANCE TEST POSITIVE |
1 |
0.0010 |
| 29 |
BONE DEMINERALISATION |
1 |
0.0009 |
| 30 |
CD4 LYMPHOCYTES DECREASED |
2 |
0.0009 |
| 31 |
STREPTOCOCCAL BACTERAEMIA |
1 |
0.0009 |
| 32 |
CENTRAL NERVOUS SYSTEM LYMPHOMA |
1 |
0.0007 |
| 33 |
MYELITIS TRANSVERSE |
1 |
0.0007 |
| 34 |
NOROVIRUS INFECTION |
1 |
0.0007 |
| 35 |
SEBORRHOEIC DERMATITIS |
1 |
0.0006 |
| 36 |
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED |
1 |
0.0006 |
| 37 |
CYTOMEGALOVIRUS CHORIORETINITIS |
1 |
0.0005 |
| 38 |
ABDOMINAL WALL HAEMATOMA |
1 |
0.0005 |
| 39 |
INJECTION SITE NECROSIS |
1 |
0.0005 |
| 40 |
GASTROINTESTINAL TUBE INSERTION |
1 |
0.0004 |
| 41 |
POSTMENOPAUSAL HAEMORRHAGE |
1 |
0.0004 |
| 42 |
MYCOBACTERIUM AVIUM COMPLEX INFECTION |
1 |
0.0004 |
| 43 |
LUNG CONSOLIDATION |
1 |
0.0004 |
| 44 |
OXYGEN SATURATION ABNORMAL |
1 |
0.0004 |
| 45 |
PANCREATIC CARCINOMA METASTATIC |
1 |
0.0004 |
| 46 |
VASCULAR GRAFT |
1 |
0.0003 |
| 47 |
ODYNOPHAGIA |
2 |
0.0003 |
| 48 |
EMERGENCY CARE |
1 |
0.0003 |
| 49 |
ALCOHOL USE |
1 |
0.0003 |
| 50 |
PARANASAL SINUS DISCOMFORT |
1 |
0.0003 |
| 51 |
INCORRECT DRUG ADMINISTRATION RATE |
1 |
0.0002 |
| 52 |
PURULENT DISCHARGE |
1 |
0.0002 |
| 53 |
LUMBAR VERTEBRAL FRACTURE |
1 |
0.0002 |
| 54 |
RASH VESICULAR |
1 |
0.0002 |
| 55 |
VITAMIN D DEFICIENCY |
2 |
0.0002 |
| 56 |
VITREOUS FLOATERS |
2 |
0.0002 |
| 57 |
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME |
1 |
0.0002 |
| 58 |
PRODUCT ADMINISTRATION ERROR |
4 |
0.0002 |
| 59 |
PRODUCT SIZE ISSUE |
1 |
0.0002 |
| 60 |
MULTIPLE USE OF SINGLE-USE PRODUCT |
1 |
0.0002 |
| 61 |
SWELLING OF EYELID |
1 |
0.0002 |
| 62 |
PHOTOPSIA |
1 |
0.0002 |
| 63 |
PRODUCT PREPARATION ISSUE |
1 |
0.0002 |
| 64 |
POST-TRAUMATIC STRESS DISORDER |
1 |
0.0001 |
| 65 |
EXTRASYSTOLES |
1 |
0.0001 |
| 66 |
PAPULE |
1 |
0.0001 |
| 67 |
ORAL DISORDER |
1 |
0.0001 |
| 68 |
TREATMENT NONCOMPLIANCE |
7 |
0.0001 |
| 69 |
PRODUCT USE COMPLAINT |
2 |
0.0001 |
| 70 |
SENSORY LOSS |
1 |
0.0001 |
| 71 |
STENT PLACEMENT |
1 |
0.0001 |
| 72 |
VENTRICULAR TACHYCARDIA |
2 |
0.0001 |
| 73 |
CANDIDA INFECTION |
2 |
0.0001 |
| 74 |
DRUG RESISTANCE |
3 |
0.0001 |
| 75 |
BLOOD MAGNESIUM DECREASED |
1 |
0.0001 |
| 76 |
ANHEDONIA |
3 |
0.0001 |
| 77 |
RETINAL DETACHMENT |
1 |
0.0001 |
| 78 |
NERVE COMPRESSION |
1 |
0.0001 |
| 79 |
NEPHROPATHY |
1 |
0.0001 |
| 80 |
FLANK PAIN |
1 |
0.0001 |
| 81 |
HOSPICE CARE |
1 |
0.0001 |
| 82 |
PNEUMOCYSTIS JIROVECII PNEUMONIA |
1 |
0.0001 |
| 83 |
SUDDEN DEATH |
1 |
0.0001 |
| 84 |
RENAL PAIN |
1 |
0.0001 |
| 85 |
BACK INJURY |
1 |
0.0001 |
| 86 |
PULMONARY THROMBOSIS |
1 |
0.0001 |
| 87 |
INJECTION SITE NODULE |
1 |
0.0001 |
| 88 |
DENTAL CARIES |
1 |
0.0001 |
| 89 |
EYE INFECTION |
1 |
0.0001 |
| 90 |
POISONING |
1 |
0.0001 |
| 91 |
GASTROINTESTINAL DISORDER |
7 |
0.0001 |
| 92 |
SARS-COV-2 TEST POSITIVE |
1 |
0.0001 |
| 93 |
EYE HAEMORRHAGE |
1 |
0.0001 |
| 94 |
RASH PRURITIC |
4 |
0.0001 |
| 95 |
DYSPHAGIA |
7 |
0.0001 |
| 96 |
BLOOD TEST ABNORMAL |
1 |
0.0001 |
| 97 |
BLINDNESS UNILATERAL |
1 |
0.0001 |
| 98 |
DIALYSIS |
1 |
0.0001 |
| 99 |
LIVER FUNCTION TEST ABNORMAL |
2 |
0.0001 |
| 100 |
APATHY |
1 |
0.0001 |
| 101 |
HAEMORRHAGE INTRACRANIAL |
1 |
0.0001 |
| 102 |
OSTEOPENIA |
1 |
0.0001 |
| 103 |
TENDONITIS |
1 |
0.0001 |
| 104 |
MUSCLE TIGHTNESS |
1 |
0.0001 |
| 105 |
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR |
2 |
0.0001 |
| 106 |
SCAR |
1 |
0.0001 |
| 107 |
INCORRECT ROUTE OF PRODUCT ADMINISTRATION |
1 |
0.0001 |
| 108 |
EOSINOPHILIA |
1 |
0.0001 |
| 109 |
HEAD DISCOMFORT |
1 |
0.0001 |
| 110 |
GOUT |
1 |
0.0001 |
| 111 |
INJECTION SITE MASS |
2 |
0.0001 |
| 112 |
HEPATIC CIRRHOSIS |
1 |
0.0001 |
| 113 |
DYSPNOEA EXERTIONAL |
2 |
0.0001 |
| 114 |
FRACTURE |
1 |
0.0001 |
| 115 |
FOOT FRACTURE |
1 |
0.0001 |
| 116 |
MUSCULOSKELETAL DISORDER |
1 |
0.0001 |
| 117 |
PRODUCT DOSE OMISSION ISSUE |
15 |
0.0001 |
| 118 |
DISABILITY |
1 |
0.0001 |
| 119 |
HALLUCINATION, VISUAL |
1 |
0.0000 |
| 120 |
RETCHING |
1 |
0.0000 |
| 121 |
BLOOD CREATININE INCREASED |
3 |
0.0000 |
| 122 |
PRODUCT PRESCRIBING ISSUE |
1 |
0.0000 |
| 123 |
CLOSTRIDIUM DIFFICILE INFECTION |
1 |
0.0000 |
| 124 |
RASH MACULO-PAPULAR |
1 |
0.0000 |
| 125 |
RASH PAPULAR |
1 |
0.0000 |
| 126 |
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS |
9 |
0.0000 |
| 127 |
PRODUCT PRESCRIBING ERROR |
1 |
0.0000 |
| 128 |
BLOOD PRESSURE FLUCTUATION |
1 |
0.0000 |
| 129 |
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES |
2 |
0.0000 |
| 130 |
INJECTION SITE URTICARIA |
1 |
0.0000 |
| 131 |
GASTRITIS |
1 |
0.0000 |
| 132 |
TREATMENT FAILURE |
3 |
0.0000 |
| 133 |
MENTAL STATUS CHANGES |
1 |
0.0000 |
| 134 |
OFF LABEL USE |
30 |
0.0000 |
| 135 |
DYSSTASIA |
1 |
0.0000 |
| 136 |
PALPITATIONS |
4 |
0.0000 |
| 137 |
RENAL INJURY |
1 |
0.0000 |
| 138 |
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION |
6 |
0.0000 |
| 139 |
BLOOD POTASSIUM DECREASED |
1 |
0.0000 |
| 140 |
LACRIMATION INCREASED |
1 |
0.0000 |
| 141 |
ILL-DEFINED DISORDER |
2 |
0.0000 |
| 142 |
BLOOD PRESSURE INCREASED |
5 |
0.0000 |
| 143 |
NERVOUS SYSTEM DISORDER |
1 |
0.0000 |
| 144 |
HIP FRACTURE |
1 |
0.0000 |
| 145 |
VIRAL INFECTION |
1 |
0.0000 |
| 146 |
SKIN DISORDER |
1 |
0.0000 |
| 147 |
TRANSIENT ISCHAEMIC ATTACK |
1 |
0.0000 |
| 148 |
ILLNESS |
3 |
0.0000 |
| 149 |
DELIRIUM |
1 |
0.0000 |
| 150 |
RASH MACULAR |
1 |
0.0000 |
| 151 |
SKIN BURNING SENSATION |
2 |
0.0000 |
| 152 |
ELECTROCARDIOGRAM QT PROLONGED |
1 |
0.0000 |
| 153 |
PANIC ATTACK |
1 |
0.0000 |
| 154 |
CHEST PAIN |
5 |
0.0000 |
| 155 |
HYPERSENSITIVITY |
5 |
0.0000 |
| 156 |
EYE SWELLING |
1 |
0.0000 |
| 157 |
COLITIS |
1 |
0.0000 |
| 158 |
CHRONIC KIDNEY DISEASE |
2 |
0.0000 |
| 159 |
HOSPITALISATION |
4 |
0.0000 |
| 160 |
RASH |
11 |
0.0000 |
| 161 |
THROMBOSIS |
2 |
0.0000 |
| 162 |
EMOTIONAL DISTRESS |
3 |
0.0000 |
| 163 |
EXTRA DOSE ADMINISTERED |
1 |
0.0000 |
| 164 |
ANXIETY |
7 |
0.0000 |
| 165 |
OSTEOPOROSIS |
1 |
0.0000 |
| 166 |
POLLAKIURIA |
1 |
0.0000 |
| 167 |
PRODUCT STORAGE ERROR |
2 |
0.0000 |
| 168 |
ANGIOEDEMA |
1 |
0.0000 |
| 169 |
DEHYDRATION |
3 |
0.0000 |
| 170 |
THERAPEUTIC RESPONSE UNEXPECTED |
1 |
0.0000 |
| 171 |
SKIN IRRITATION |
1 |
0.0000 |
| 172 |
BACK PAIN |
5 |
0.0000 |
| 173 |
NAUSEA |
17 |
0.0000 |
| 174 |
DISEASE RECURRENCE |
1 |
0.0000 |
| 175 |
PRODUCTIVE COUGH |
1 |
0.0000 |
| 176 |
RASH ERYTHEMATOUS |
1 |
0.0000 |
| 177 |
MULTIPLE SCLEROSIS |
1 |
0.0000 |
| 178 |
DRUG INTOLERANCE |
2 |
0.0000 |
| 179 |
HYPOGLYCAEMIA |
1 |
0.0000 |
| 180 |
HEART RATE INCREASED |
2 |
0.0000 |
| 181 |
DIZZINESS |
10 |
0.0000 |
| 182 |
HYPOAESTHESIA |
3 |
0.0000 |
| 183 |
INJECTION SITE PAIN |
6 |
0.0000 |
| 184 |
INFLAMMATION |
1 |
0.0000 |
| 185 |
NERVOUSNESS |
1 |
0.0000 |
| 186 |
MUSCULOSKELETAL PAIN |
1 |
0.0000 |
| 187 |
ASTHENIA |
7 |
0.0000 |
| 188 |
DEATH |
16 |
0.0000 |
| 189 |
ARTHROPATHY |
1 |
0.0000 |
| 190 |
INFLUENZA |
2 |
0.0000 |
| 191 |
URTICARIA |
3 |
0.0000 |
| 192 |
NECK PAIN |
1 |
0.0000 |
| 193 |
PANCYTOPENIA |
1 |
0.0000 |
| 194 |
ABDOMINAL DISCOMFORT |
3 |
0.0000 |
| 195 |
MUSCULAR WEAKNESS |
2 |
0.0000 |
| 196 |
INCORRECT DOSE ADMINISTERED |
4 |
0.0000 |
| 197 |
WHEEZING |
1 |
0.0000 |
| 198 |
DISCOMFORT |
1 |
0.0000 |
| 199 |
NASOPHARYNGITIS |
3 |
0.0000 |
| 200 |
EXPOSURE DURING PREGNANCY |
1 |
0.0000 |
| 201 |
PRODUCT USE ISSUE |
3 |
0.0000 |
| 202 |
GAIT DISTURBANCE |
3 |
0.0000 |
| 203 |
SWELLING FACE |
1 |
0.0000 |
| 204 |
BLOOD PRESSURE DECREASED |
1 |
0.0000 |
| 205 |
DRY SKIN |
2 |
0.0000 |
| 206 |
INJECTION SITE PRURITUS |
1 |
0.0000 |
| 207 |
WEIGHT DECREASED |
4 |
0.0000 |
| 208 |
HYPERTENSION |
3 |
0.0000 |
| 209 |
THERAPY INTERRUPTED |
1 |
0.0000 |
| 210 |
MOBILITY DECREASED |
1 |
0.0000 |
| 211 |
DYSGEUSIA |
1 |
0.0000 |
| 212 |
HALLUCINATION |
1 |
0.0000 |
| 213 |
DEPRESSION |
3 |
0.0000 |
| 214 |
CONDITION AGGRAVATED |
4 |
0.0000 |
| 215 |
DIABETES MELLITUS |
1 |
0.0000 |
| 216 |
PERIPHERAL SWELLING |
2 |
0.0000 |
| 217 |
FATIGUE |
10 |
0.0000 |
| 218 |
PARAESTHESIA |
2 |
0.0000 |
| 219 |
INJECTION SITE HAEMORRHAGE |
1 |
0.0000 |
| 220 |
GASTROOESOPHAGEAL REFLUX DISEASE |
1 |
0.0000 |
| 221 |
DIARRHOEA |
8 |
0.0000 |
| 222 |
FOETAL EXPOSURE DURING PREGNANCY |
1 |
0.0000 |
| 223 |
CEREBROVASCULAR ACCIDENT |
2 |
0.0000 |
| 224 |
INTENTIONAL PRODUCT MISUSE |
1 |
0.0000 |
| 225 |
COVID-19 |
2 |
0.0000 |
| 226 |
PAIN |
7 |
0.0000 |
| 227 |
INSOMNIA |
3 |
0.0000 |
| 228 |
TACHYCARDIA |
1 |
0.0000 |
| 229 |
MATERNAL EXPOSURE DURING PREGNANCY |
1 |
0.0000 |
| 230 |
OROPHARYNGEAL PAIN |
1 |
0.0000 |
| 231 |
CARDIAC DISORDER |
1 |
0.0000 |
| 232 |
SWELLING |
1 |
0.0000 |
| 233 |
VOMITING |
5 |
0.0000 |
| 234 |
DRUG INEFFECTIVE |
14 |
0.0000 |
| 235 |
DYSPNOEA |
6 |
0.0000 |
| 236 |
PULMONARY EMBOLISM |
1 |
0.0000 |
| 237 |
MIGRAINE |
1 |
0.0000 |
| 238 |
SYNCOPE |
1 |
0.0000 |
| 239 |
FLUSHING |
1 |
0.0000 |
| 240 |
CHEST DISCOMFORT |
1 |
0.0000 |
| 241 |
HAEMOGLOBIN DECREASED |
1 |
0.0000 |
| 242 |
ABDOMINAL PAIN UPPER |
2 |
0.0000 |
| 243 |
ABDOMINAL DISTENSION |
1 |
0.0000 |
| 244 |
HEADACHE |
6 |
0.0000 |
| 245 |
FALL |
3 |
0.0000 |
| 246 |
SEPSIS |
1 |
0.0000 |
| 247 |
ASTHMA |
1 |
0.0000 |
| 248 |
CHILLS |
1 |
0.0000 |
| 249 |
DISEASE PROGRESSION |
1 |
0.0000 |
| 250 |
OEDEMA PERIPHERAL |
1 |
0.0000 |
| 251 |
INJECTION SITE ERYTHEMA |
1 |
0.0000 |
| 252 |
PRURITUS |
3 |
0.0000 |
| 253 |
HYPERHIDROSIS |
1 |
0.0000 |
| 254 |
COUGH |
2 |
0.0000 |
| 255 |
PAIN IN EXTREMITY |
2 |
0.0000 |
| 256 |
DRUG INTERACTION |
1 |
0.0000 |
| 257 |
CONFUSIONAL STATE |
1 |
0.0000 |
| 258 |
PNEUMONIA |
2 |
0.0000 |
| 259 |
MYALGIA |
1 |
0.0000 |
| 260 |
PYREXIA |
2 |
0.0000 |
| 261 |
BLOOD GLUCOSE INCREASED |
1 |
0.0000 |
| 262 |
ANAEMIA |
1 |
0.0000 |
| 263 |
ALOPECIA |
1 |
0.0000 |
| 264 |
SOMNOLENCE |
1 |
0.0000 |
| 265 |
ERYTHEMA |
1 |
0.0000 |
| 266 |
ARTHRALGIA |
2 |
0.0000 |
| 267 |
MALAISE |
2 |
0.0000 |
| 268 |
DECREASED APPETITE |
1 |
0.0000 |
| 269 |
ABDOMINAL PAIN |
1 |
0.0000 |
| 270 |
FEELING ABNORMAL |
1 |
0.0000 |
| 271 |
PRODUCT USE IN UNAPPROVED INDICATION |
1 |
0.0000 |